Subscribe to Search results

The Department of Health responded to the British Liver Trust stating that "The majority of patients who will have been at risk of exposure to hepatitis C have been tested for Hepatitis C and following further investigation are being treated with alpha interferon where it is considered clinically appropriate."

Published on:

It was noted there was a tension between the need for a central initiative to deal with Hepatitis C and the aim of leaving the NHS to determine its own priorities based on assessment of local needs and there was a need to confirm whether to maintain the line in response to requests for departmental action on additional resources.

Published on:

Dr Metters was told that the commitment given was to provide treatment for Hepatitis C where appropriate or necessary and that there had been no firm commitment to provide treatment in every case.

Published on:

Document showing extracts from debates and questions about the lookback exercise and haemophilia and Hepatitis C.

Published on:

There was a ministerial commitment "to investigate allegations of problems of access to alpha interferon."

Published on:

A paper on Hepatitis C was prepared for a meeting of the NHS Executive stated: "The cost of treatment with alpha interferon (£2-5,000/patient) is already placing a considerable burden on purchasers and the pressure to prescribe Alpha Interferon widely is growing."

Published on:

The NHS Executive Board agreed that measures needed to be taken in the interests of public health, but reached no conclusion as to guidance or what should be funded.

Published on:

The paper on Hepatitis C discussed at a meeting of the NHS Executive Board on 13/14 June was provided to the CMO.

Published on:

The CMO and colleagues from the Department of Health had a meeting. The NHS Executive Board had not yet come to a firm view on funding of interferon treatment, and a cautious approach was necessary.

Published on:

There was an internal meeting at the Department of Health to discuss Hepatitis C and Alpha Interferon. There was thought to be "a strong case, on public health grounds, for at least developing clinical guidelines on the management of HCV, including the use of Alpha Interferon."

Published on:

Officials made the decision not to recommend issuing purchasing guidelines due to the likelihood the issue would have on health authorities.

Published on:

A final submission was sent to the office of the Parliamentary Under-Secretary of State for Health, John Horam, highlighting the increased expectations of Hepatitis C treatment, particularly for those infected through receiving blood transfusions and blood products, following the lookback exercise.

Published on:

It was recommended that the Department of Health did not issue any purchasing guidance as it may be read as giving "an implicit signal to purchasers about the priority to be attached to a particular condition or treatment" which purchasers would not welcome.

Published on:

The annex to a submission regarding Hepatitis C noted: "Ministers have given commitments to help, including investigating alleged problems of access to Alpha Interferon for [haemophiliacs]. So far the few cases identified have been readily resolved."

Published on:

John Horam noted that providing different treatment to people depending on how they were infected with Hepatitis C would be controversial.

Published on:

The Secretary of State suggested that "GPs should have a greater role in identifying, diagnosing, treating and referring HCV as appropriate, and that GP involvement should be secured..."

Published on:

Professor Sir Kenneth Calman noted that "The direction of policy seems then to have been set and did not change throughout 1997, including after the General Election of May 1997 and subsequent change of government."

Published on:

Professor Sir Kenneth Calman noted that the issues surrounding inability to access interferon treatment for Hepatitis C "were common across the NHS when new drugs or treatments emerged."

Published on:

Professor Sir Kenneth Calman stated: "The decision in early 1998 to provide central funds to make recombinant products more widely available was driven...by the understandable fear felt by haemophilia patients and their carers in the face of the unknown but theoretical risk of vCJD and against a background of infection with blood borne viruses."

Published on:

A policy submission was sent to the offices of the CMO and the Ministers of State, Tessa Jowell and Baroness Margaret Jay. It noted that some health authorities were refusing to fund alpha interferon due to its cost and belief it was of limited clinical effectiveness.

Published on: